CT Misdiagnosis Risk in Soft Tissue Tumors: CT Discovery, MRI Characterization, and the Radiologic Clues That Matter
Executive Clinical Summary
A small superficial soft-tissue nodule may appear insignificant on an initial CT examination, particularly when it is discovered incidentally during imaging performed for an unrelated clinical complaint. Yet size alone does not determine the diagnostic importance of a soft-tissue mass.
This case illustrates that principle clearly.
A woman in her 40s underwent CT angiography of the chest, abdomen, and pelvis during evaluation of chest pain. The examination incidentally demonstrated a superficial soft-tissue nodule in the right buttock measuring approximately 2.1 × 1.6 cm. The lesion was not described as a typical fatty mass and was located within the superficial subcutaneous tissues.
Approximately three years later, MRI demonstrated enlargement to approximately 3–4 cm. The lesion was slightly hypointense to skeletal muscle on T1-weighted imaging and markedly hyperintense on T2-weighted sequences. Thin internal low-signal linear structures were present. After contrast administration, the lesion demonstrated strong enhancement, with conspicuous vascular structures around its anterior aspect.
The final diagnostic consideration was myxoid solitary fibrous tumor (myxoid SFT).
The diagnostic value of this case lies not in any single imaging feature, but in the combination of findings: interval growth, non-fatty soft-tissue composition, very high T2 signal, internal low-signal fibrous structures, strong enhancement, and conspicuous peritumoral vascularity.
The case also demonstrates an important MRI interpretation principle: not every dark or bright line seen at a tumor margin represents tumor histology. In this case, a boundary signal abnormality on sagittal T2-weighted imaging was interpreted as a type 1 chemical-shift artifact rather than intrinsic tumor architecture.
Key Clinical Questions
When a small superficial soft-tissue mass is encountered on CT, several questions should immediately arise:
Is the lesion truly fatty, cystic, vascular, neural, or solid soft tissue?
Has the lesion changed in size compared with previous imaging?
What does its T1 signal tell us about tissue composition?
Why is the lesion markedly hyperintense on T2-weighted imaging?
Does the lesion enhance internally?
Are there prominent vessels around the mass?
Is there a fibrous component producing low-signal structures?
Does the lesion involve the fascia, muscle, nerve, or adjacent structures?
Could an imaging artifact be mistaken for a pathologic finding?
When should a seemingly small incidental lesion undergo further characterization?
These questions provide a more reliable diagnostic framework than simply asking whether a lesion is "small" or "large."
Introduction: When an Incidental Finding Changes the Diagnostic Conversation
The original clinical problem in this case was chest pain. The buttock lesion was an incidental finding, and there is no evidence in the available clinical information that the buttock mass caused the patient's chest pain.
That distinction matters.
Incidental findings are common in modern imaging, particularly when CT examinations cover large anatomic regions. The radiologist must decide which incidental abnormalities can be safely characterized as benign and which require additional evaluation.
A superficial soft-tissue nodule that is clearly composed of macroscopic fat and demonstrates classic imaging characteristics may require a different approach from a non-fatty, enhancing lesion.
In this case, the initial CT provided the first clue: the lesion was a small soft-tissue nodule rather than an obviously fatty mass.
Three years later, MRI provided a substantially richer tissue characterization profile.
The lesson is straightforward:
The diagnostic meaning of a soft-tissue mass comes from its composition, signal characteristics, enhancement, vascularity, anatomic relationships, and temporal behavior—not from size alone.
Learning Objectives
By the end of this article, readers should be able to:
Recognize the major CT and MRI features of the presented myxoid SFT.
Explain how myxoid and collagenous tissue components can produce different MRI signals.
Distinguish myxoid SFT from common mimics such as lipoma, cystic lesions, vascular lesions, and other myxoid tumors.
Understand why strong enhancement and peritumoral vascularity are diagnostically important.
Recognize chemical-shift artifact and avoid mistaking it for intrinsic tumor architecture.
Apply a structured seven-step approach to superficial soft-tissue masses.
Case Presentation
Clinical Setting
A woman in her 40s underwent CT angiography of the chest, abdomen, and pelvis because of chest pain.
The available case information does not establish a direct relationship between the chest pain and the buttock lesion.
During the examination, a superficial nodule was incidentally identified in the right buttock.
The initial CT demonstrated a relatively well-defined soft-tissue nodule measuring approximately 2.1 × 1.6 cm.
The lesion was located within the superficial subcutaneous tissues and did not demonstrate the typical appearance of a simple fatty lesion.
Approximately three years later, MRI demonstrated enlargement of the lesion to approximately 3–4 cm.
The MRI findings included:
Slightly low T1 signal relative to skeletal muscle
Markedly high T2 signal
Thin internal low-signal linear structures
Strong post-contrast enhancement
Prominent vascular structures around the lesion
A superficial location without obvious deep fascial or muscular invasion in the described imaging
The final diagnosis considered in this case was myxoid solitary fibrous tumor.
Detailed operative and histopathologic findings are not provided in the available clinical information and therefore should not be inferred beyond the stated diagnosis.
CT: The First Clue Was That the Lesion Was Not Obviously Fat
Figure 1. Axial CT angiography demonstrating the incidental superficial right buttock soft-tissue nodule.
Radiologist Interpretation:
A relatively well-defined approximately 2.1 × 1.6 cm soft-tissue attenuation nodule is present within the superficial subcutaneous tissue of the right buttock. The lesion is distinguishable from surrounding subcutaneous fat and is not described as a deeply located mass or one with definite fascial invasion.
Clinical Significance:
The most useful first question is not whether the lesion is small. It is whether the lesion has the expected composition of a benign fatty lesion.
The CT finding therefore establishes the first branch of the diagnostic pathway:
Superficial nodule → non-fatty soft-tissue attenuation → further characterization may be appropriate.
Three-Year Interval Change: Growth Matters, but Growth Does Not Equal Malignancy
The subsequent MRI examination demonstrated that the lesion had increased from approximately 2 cm to approximately 3–4 cm.
Interval growth is an important imaging observation.
However, the statement "growth equals malignancy" is not justified.
Likewise, the opposite assumption—"small means benign"—is equally unreliable.
For solitary fibrous tumors, biological behavior is influenced by multiple clinical and histopathologic variables, including age, tumor size, mitotic activity, and necrosis. Risk assessment therefore requires more than measurement alone.
The appropriate interpretation is:
Interval growth increases the need for characterization, but does not independently establish malignant behavior.
That distinction is especially important for rare tumors such as myxoid SFT, for which the published literature is limited.
MRI: Where Tissue Characterization Becomes the Key
T2-Weighted Imaging
Figure 2. Axial T2-weighted MRI demonstrating marked hyperintensity of the lesion.
Radiologist Interpretation:
The lesion demonstrates markedly increased T2 signal relative to skeletal muscle. Thin internal low-signal linear structures are also visible.
Clinical Significance:
Marked T2 hyperintensity suggests a tissue component with relatively high free-water content. In the context of myxoid SFT, abundant myxoid stroma provides a plausible histologic correlate for the high T2 signal.
The critical point, however, is that T2 hyperintensity is nonspecific.
Many lesions can appear very bright on fluid-sensitive MRI sequences.
Therefore:
T2 bright ≠ myxoid SFT.
The diagnostic value comes from combining the T2 appearance with the other findings.
Sagittal T2-Weighted Imaging and the Importance of MRI Artifacts
Figure 3. Sagittal T2-weighted MRI demonstrating the markedly hyperintense superficial mass.
The sagittal images also demonstrate an educationally important phenomenon.
A dark signal band is present along one boundary of the lesion, with a corresponding bright band on the opposite side.
This appearance can potentially be mistaken for intrinsic tumor architecture.
In the presented case, however, the finding is interpreted as a type 1 chemical-shift artifact related to the frequency-encoding direction.
This is an important radiologic lesson:
Not every signal pattern is pathology.
Chemical-shift artifact results from the difference in resonance frequencies between fat and water. Depending on imaging parameters and encoding direction, it may create alternating bright and dark bands at fat-water interfaces.
Recognizing this phenomenon prevents an artifact from being incorrectly incorporated into the tumor's histologic interpretation.
Fat-Suppressed T2 Imaging: Making the Lesion More Obvious
Figure 4. Axial T2-weighted fat-suppressed MRI demonstrating high signal intensity of the lesion.
Radiologist Interpretation:
Fat suppression reduces the signal from surrounding subcutaneous fat, increasing lesion-to-background contrast. The lesion remains markedly hyperintense.
Clinical Significance:
The combination of high T2 signal and suppressed surrounding fat makes the lesion's morphology and boundaries easier to appreciate.
Figure 5. Sagittal T2-weighted fat-suppressed MRI demonstrating marked hyperintensity of the superficial mass.
The high signal remains conspicuous on sagittal fat-suppressed imaging.
This imaging appearance can be understood in relation to tissue composition:
| Imaging Finding | Possible Tissue Correlate |
|---|---|
| Very high T2 signal | Myxoid / water-rich matrix |
| Low-signal internal lines | Fibrous or collagenous tissue |
| Strong enhancement | Vascularized solid tissue |
| Prominent peritumoral vessels | Vascular component |
| Non-fatty CT attenuation | Solid soft-tissue composition |
This is more informative than interpreting any individual sequence in isolation.
T1-Weighted Imaging: Why the Lesion Does Not Behave Like a Typical Lipoma
Figure 6. Axial T1-weighted MRI demonstrating slightly lower signal intensity than skeletal muscle.
The lesion is slightly hypointense relative to skeletal muscle on T1-weighted imaging.
This finding is important because macroscopic fat generally demonstrates high T1 signal.
Therefore, the lesion does not demonstrate the classic MRI pattern expected of a simple lipoma.
Figure 7. Axial T1-weighted fat-suppressed MRI demonstrating the lesion and its internal architecture.
The T1-weighted findings reinforce the initial CT impression that this is not a typical fatty subcutaneous mass.
From a radiologic perspective, the sequence of reasoning is:
Non-fatty CT attenuation → low/slightly low T1 signal → markedly high T2 signal → consider water-rich soft-tissue composition rather than macroscopic fat.
Contrast Enhancement: The Finding That Changes the Differential
Figure 8. Axial T1-weighted fat-suppressed post-contrast MRI demonstrating strong enhancement.
The lesion demonstrates conspicuous enhancement after contrast administration.
This observation is diagnostically important because a very T2-bright lesion might initially suggest a cystic or fluid-dominant process.
However, substantial internal enhancement argues against a simple cyst.
A simple cyst generally contains fluid without enhancing solid internal tissue.
Here, strong enhancement indicates that the lesion contains vascularized tissue.
The diagnostic pathway therefore changes:
Very high T2 signal + strong enhancement → a vascularized solid soft-tissue lesion should be considered.
Peritumoral Vascularity: A Particularly Useful Clue
Figure 9. Sagittal T1-weighted fat-suppressed MRI demonstrating the superficial mass.
Figure 10. Sagittal T1-weighted fat-suppressed post-contrast MRI demonstrating strong enhancement and prominent vessels adjacent to the lesion.
The conspicuous vessels around the lesion are an important feature of the case.
SFTs can demonstrate prominent vascularity and strong enhancement.
This leads to one of the most useful questions in the evaluation of an enhancing soft-tissue mass:
Is the lesion simply a superficial nodule, or is it a vascularized soft-tissue neoplasm?
In this case, the combination of strong enhancement and conspicuous adjacent vessels supports the latter consideration.
Understanding Myxoid Solitary Fibrous Tumor
Solitary fibrous tumor is a rare mesenchymal neoplasm that can arise in numerous anatomic locations.
Historically, SFTs were described under different names according to location and morphology. Modern pathologic classification recognizes them as part of a broader tumor spectrum.
A characteristic molecular event associated with SFT is the NAB2–STAT6 fusion, with STAT6 immunohistochemistry playing an important role in pathologic diagnosis.
The tumor may contain:
Spindle cells
Collagenous stroma
Variable cellularity
Prominent vascular structures
Myxoid stroma in myxoid variants
These components have direct implications for imaging.
Why Is This Tumor Called "Myxoid"?
The term myxoid refers to abundant myxoid stroma.
Myxoid tissue contains a substantial amount of water-rich extracellular matrix. On MRI, this can produce high signal intensity on T2-weighted and fluid-sensitive sequences.
This creates an interesting imaging combination.
The conventional fibrous component can contribute to low-signal structures, whereas the myxoid component can produce striking T2 hyperintensity.
Therefore, the MRI may contain both:
dark fibrous elements + bright myxoid elements
This mixed signal pattern provides a bridge between radiology and pathology.
The "Black-and-White" Appearance of SFT
SFTs may show a mixture of relatively low- and high-signal components.
A low-signal component can correspond to collagen-rich tissue, while higher-signal regions may reflect increased cellularity or water-rich tissue.
In a myxoid SFT, the high-signal component can become particularly conspicuous.
This helps explain why the presented lesion is not simply "a bright T2 tumor."
The more informative description is:
A markedly T2-hyperintense superficial soft-tissue mass containing thin low-signal internal structures and demonstrating strong enhancement with prominent adjacent vessels.
That description carries considerably more diagnostic information.
Differential Diagnosis
A superficial T2-hyperintense soft-tissue mass has a broad differential diagnosis.
| Diagnosis | Key Imaging Finding | Clinical / Anatomic Clue | Differentiating Point |
|---|---|---|---|
| Lipoma | T1 high signal, fat suppression | Common superficial mass | Macroscopic fat should be evident |
| Liposarcoma | Fat plus non-fatty components | Larger or complex lesion | Thick septa, nodular non-fatty components |
| Hemangioma / vascular lesion | T2 high signal and vascularity | Vascular structures | Flow-related findings and vascular architecture |
| Lymphatic malformation | Fluid-rich high T2 signal | Often multiloculated | Cystic architecture rather than strongly enhancing solid tissue |
| Schwannoma | T2 high signal | Nerve relationship | Neural continuity and characteristic internal signs |
| Neurofibroma | T2 high signal | Nerve-associated lesion | Target or fascicular patterns may be present |
| Leiomyosarcoma | Soft-tissue mass with variable signal | Potentially aggressive | Necrosis, hemorrhage, irregular enhancement |
| Epithelioid sarcoma | Superficial soft-tissue lesion | Potentially aggressive | Pathologic correlation required |
| Metastasis | Variable signal and enhancement | Known primary malignancy may help | Clinical history and multiplicity |
| Other myxoid tumor | Often high T2 signal | Variable | Histologic differentiation may be necessary |
| Myxoid SFT | High T2 + low-signal fibrous structures + strong enhancement + vascularity | Superficial or deep soft-tissue location | Combination of myxoid and fibrous/vascular features |
The key principle is that T2 hyperintensity is a starting point, not a diagnosis.
Why This Lesion Is Not a Typical Lipoma
Lipoma is an obvious consideration for a superficial buttock mass because it is common.
However, the imaging characteristics in this case are not typical for a simple lipoma.
The lesion:
Was not described as fatty on CT.
Was slightly low rather than high in T1 signal.
Remained conspicuously bright on T2.
Demonstrated strong enhancement.
Had prominent adjacent vessels.
This constellation moves the differential away from a straightforward lipoma.
Why This Lesion Is Not a Simple Cyst
The lesion is extremely bright on T2-weighted imaging and could therefore superficially resemble a fluid-containing lesion.
But strong internal enhancement changes the interpretation.
A simple cyst does not normally demonstrate substantial enhancement of its internal contents.
This distinction is fundamental in soft-tissue MRI.
Pathology-Imaging Correlation
The imaging findings can be conceptually connected to the expected tissue components of SFT.
| Histologic Component | Imaging Correlation |
|---|---|
| Collagenous stroma | Relatively low MRI signal |
| Myxoid stroma | High T2 signal |
| Vascular component | Strong enhancement and visible vessels |
| Cellular component | Variable signal and enhancement |
| Mixed tissue composition | Heterogeneous or mixed signal appearance |
This correlation should not be interpreted as a substitute for histopathology.
Rather, it demonstrates how MRI can provide a noninvasive representation of the underlying tissue composition.
Doege–Potter Syndrome: An Important Clinical Association
An additional clinical association of SFT is Doege–Potter syndrome, a paraneoplastic hypoglycemic syndrome related to excessive production of IGF-2 or IGF-2-related peptides.
It is uncommon and should not be assumed to be present in every patient with SFT.
However, when an unexplained episode of hypoglycemia occurs in a patient with a substantial SFT, this association may be clinically relevant.
The available case information does not report hypoglycemia or Doege–Potter syndrome in this patient.
Treatment Considerations
For a localized, surgically resectable SFT, complete surgical excision is generally central to management.
However, treatment decisions depend on the individual lesion and its biological risk profile.
Relevant considerations include:
Tumor size
Anatomic location
Relationship to adjacent structures
Resectability
Histologic characteristics
Mitotic activity
Necrosis
Cellular characteristics
Recurrence
Metastatic disease
The available case material does not provide sufficient operative details or a documented postoperative outcome to describe an individual treatment course.
It is therefore more accurate to regard the presented case as an imaging-centered diagnostic case rather than to infer a specific surgical outcome.
Prognosis: Why "Myxoid" Does Not Automatically Mean Benign
Myxoid SFT is rare, and the available literature consists substantially of small case series and individual reports.
Small published series have described relatively favorable courses in some patients with myxoid SFT, but the sample sizes are too limited to establish that every myxoid SFT behaves indolently.
SFT as a broader entity can recur or metastasize.
Risk assessment therefore considers clinical and pathologic variables rather than relying on the word "myxoid" alone.
Potentially concerning features include:
Definite interval growth
Rapid enlargement
Necrosis
Hemorrhage
Infiltrative margins
Increasing cellularity
Increased mitotic activity
Recurrence
Metastatic disease
Thus, the appropriate conclusion is not that a myxoid SFT is benign or malignant simply because of its myxoid morphology.
CT Versus MRI: Complementary Roles
| Modality | Major Strength | Limitation in This Case | Main Clinical Question |
|---|---|---|---|
| CT | Detection, anatomy, attenuation, fat/soft-tissue distinction | Limited soft-tissue contrast compared with MRI | Is there an abnormal soft-tissue mass? |
| MRI | Tissue characterization and local anatomic assessment | More complex and time-consuming | What is the lesion composed of and how does it relate to surrounding structures? |
| Contrast-enhanced MRI | Vascularity and enhancement | Requires contrast administration | Is the lesion vascularized, and how does it enhance? |
The case demonstrates a complementary imaging pathway rather than a competition between CT and MRI.
CT detected the lesion. MRI characterized it.
A Seven-Step Radiologic Approach to a Superficial Soft-Tissue Mass
Step 1 — Determine the Anatomic Layer
Is the lesion:
Dermal?
Subcutaneous?
Fascial?
Intramuscular?
Intermuscular?
Localization immediately narrows the differential diagnosis.
Step 2 — Measure It
Document the maximum dimensions and compare them with prior imaging whenever possible.
Step 3 — Determine Composition
Ask whether the lesion is:
Fat
Fluid
Solid soft tissue
Mixed
Calcified
Step 4 — Analyze T1 Signal
Compare the lesion with:
Subcutaneous fat
Skeletal muscle
Fluid
T1 signal is particularly useful for identifying macroscopic fat.
Step 5 — Analyze T2 Signal
Ask whether the lesion is:
Low signal
Intermediate signal
High signal
Markedly high signal
Then determine whether internal low-signal fibrous structures are present.
Step 6 — Evaluate Enhancement
Determine whether enhancement is:
Absent
Mild
Moderate
Strong
Homogeneous
Heterogeneous
Step 7 — Evaluate Vessels and Adjacent Structures
Look specifically for:
Peritumoral vessels
Fascial involvement
Muscle invasion
Nerve relationship
Bone involvement
Necrosis
Hemorrhage
This structured approach is more reliable than pattern recognition based on one MRI sequence.
Artificial Intelligence Perspective
AI is increasingly being incorporated into radiology workflows, but a rare tumor such as myxoid SFT presents a difficult AI problem.
A detection model may identify an abnormal soft-tissue mass, but detection is not equivalent to diagnosis.
A clinically useful AI system could potentially support several stages:
DICOM → AI detection → lesion localization → segmentation → quantitative analysis → PACS visualization → radiologist review
Potential AI tasks include:
Automated detection of superficial soft-tissue masses
Lesion segmentation
Longitudinal size comparison
Quantification of T1/T2 signal characteristics
Enhancement analysis
Vascularity assessment
Comparison with prior examinations
Retrieval of similar imaging patterns
Structured reporting assistance
However, a rare tumor such as myxoid SFT exposes an important limitation of machine learning.
If training datasets contain few examples of the disease, the model may have difficulty generalizing to real-world cases.
A system trained predominantly on common lipomas, cysts, sarcomas, and vascular lesions could potentially classify an unusual myxoid SFT incorrectly.
Therefore, an AI output should function as decision support rather than diagnostic authority.
AI Failure Modes in Rare Soft-Tissue Tumors
Several failure modes deserve attention:
| AI Failure Mode | Potential Consequence | Radiologist Verification |
|---|---|---|
| False negative | Lesion overlooked | Review source images and prior studies |
| False positive | Unnecessary workup | Confirm morphology and clinical context |
| Mislocalization | Incorrect anatomic interpretation | Verify lesion layer |
| Poor segmentation | Incorrect size/volume | Check lesion boundaries manually |
| Domain shift | Reduced performance on unfamiliar scanners or populations | Assess image quality and context |
| Rare-disease underrepresentation | Incorrect classification | Consider uncommon diagnoses |
| Enhancement misinterpretation | Cyst mistaken for solid lesion or vice versa | Review pre- and post-contrast images |
| Temporal comparison error | Incorrect assessment of growth | Verify prior study dates and measurements |
The most valuable AI capability in such a case may therefore not be "naming the tumor."
It may be recognizing that the lesion has changed and directing the radiologist toward the relevant prior examination.
Enterprise Imaging Workflow
For a hospital-scale environment, an AI-supported soft-tissue mass workflow could be structured as:
The system should preserve the radiologist's ability to inspect the original images.
AI-derived measurements, segmentation overlays, and confidence information should remain clearly distinguishable from the source imaging.
For rare tumors, auditability is particularly important because a retrospective review may be required when the AI system produces an unexpected recommendation.
Ten Expert Insights
Expert Insight 1 — Radiologist Perspective
A small superficial lesion should be characterized by tissue composition and behavior rather than dismissed because of its size.
Expert Insight 2 — MRI Perspective
Marked T2 hyperintensity is a tissue clue, not a diagnosis. The surrounding imaging context determines its significance.
Expert Insight 3 — Pathology Perspective
The combination of myxoid and collagenous components provides a plausible explanation for the mixture of bright and dark MRI signals.
Expert Insight 4 — Vascular Perspective
Prominent vessels around a strongly enhancing mass should raise consideration of a vascularized soft-tissue neoplasm.
Expert Insight 5 — Temporal Imaging Perspective
Prior imaging can transform an apparently minor incidental finding into a clinically meaningful longitudinal observation.
Expert Insight 6 — MRI Physics Perspective
Chemical-shift artifact can mimic tumor architecture. Recognizing artifact is part of accurate image interpretation.
Expert Insight 7 — Differential Diagnosis Perspective
The correct question is not "What is a T2-bright mass?" but "What is a T2-bright, strongly enhancing, non-fatty mass with internal low-signal structures and adjacent vessels?"
Expert Insight 8 — Clinical Workflow Perspective
Automated comparison with prior examinations may be more clinically valuable than simply flagging the lesion on the current study.
Expert Insight 9 — AI Deployment Perspective
Rare tumors expose dataset limitations. A model's performance on common masses cannot automatically be extrapolated to rare entities.
Expert Insight 10 — Patient Journey Perspective
An incidental finding can become diagnostically important years later. Longitudinal imaging therefore represents a clinical resource rather than merely an archive.
Clinical Pearls
A small superficial soft-tissue mass is not automatically benign.
CT can provide the first critical clue by demonstrating non-fatty soft-tissue attenuation.
Interval growth warrants characterization but does not independently establish malignancy.
Markedly high T2 signal can reflect myxoid, water-rich tissue.
Thin internal low-signal structures may reflect fibrous or collagenous components.
Strong internal enhancement argues against a simple cyst.
Prominent vessels may suggest a vascularized soft-tissue neoplasm.
Myxoid SFT can combine the imaging characteristics of myxoid and fibrous tissue.
Chemical-shift artifact should not be mistaken for tumor histology.
MRI provides substantially greater soft-tissue characterization than the initial CT in this case.
SFT risk assessment requires clinical and pathologic information beyond MRI signal intensity.
A myxoid morphology alone should not be interpreted as proof of benign behavior.
Common Diagnostic Pitfalls
Pitfall 1 — Calling It a Lipoma Because It Is Superficial
Superficial location does not establish a fatty diagnosis.
Pitfall 2 — Calling It a Cyst Because It Is Very Bright on T2
Strong internal enhancement argues against a simple cyst.
Pitfall 3 — Ignoring Prior Imaging
The increase from approximately 2 cm to 3–4 cm provides important longitudinal information.
Pitfall 4 — Treating Every Dark Line as Tumor
Chemical-shift artifact can create apparent boundary structures.
Pitfall 5 — Using T2 Signal Alone
T2 hyperintensity is nonspecific and must be interpreted together with T1 signal, enhancement, vascularity, and anatomy.
Pitfall 6 — Assuming Myxoid Means Benign
The biological behavior of SFT requires broader clinical and pathologic risk assessment.
Pitfall 7 — Overreliance on AI Classification
Rare diseases may be underrepresented in training datasets. Human image review remains essential.
Frequently Asked Questions
What is a myxoid solitary fibrous tumor?
A myxoid solitary fibrous tumor is a rare variant of solitary fibrous tumor characterized by prominent myxoid stroma. The myxoid component can produce marked T2 hyperintensity on MRI.
What is the characteristic MRI pattern in this case?
The major findings are slightly low T1 signal, marked T2 hyperintensity, thin internal low-signal linear structures, strong contrast enhancement, and prominent vessels around the lesion.
Why is the lesion not a typical lipoma?
The lesion demonstrates non-fatty CT attenuation and slightly low T1 signal rather than the high T1 signal expected from macroscopic fat.
Why is it not a simple cyst?
Although the lesion is very bright on T2-weighted imaging, it demonstrates strong enhancement, indicating vascularized tissue rather than simple fluid.
Why are the surrounding vessels important?
Prominent vessels together with strong enhancement suggest a vascularized solid soft-tissue lesion and are compatible with the vascular characteristics recognized in SFT.
Does growth prove malignancy?
No. Interval growth is clinically important but does not by itself establish malignant behavior.
What molecular abnormality is associated with SFT?
NAB2–STAT6 fusion is a characteristic molecular feature of SFT and is associated with nuclear STAT6 expression used in pathologic diagnosis.
What is Doege–Potter syndrome?
It is a rare paraneoplastic hypoglycemic syndrome associated with excessive IGF-2-related activity in some patients with SFT.
Is MRI sufficient to definitively diagnose myxoid SFT?
Imaging can strongly suggest the diagnosis, but definitive diagnosis generally requires appropriate pathologic correlation.
What is the main radiologic lesson from this case?
A superficial soft-tissue mass should be interpreted by integrating its composition, signal characteristics, enhancement, vascularity, anatomic relationships, and interval change rather than relying on size or one MRI sequence.
Quiz
Question 1
A superficial buttock mass demonstrates slightly low T1 signal, marked T2 hyperintensity, thin internal low-signal structures, strong enhancement, and prominent adjacent vessels. Which diagnosis should be considered?
① Lipoma
② Simple cyst
③ Myxoid solitary fibrous tumor
④ Simple hematoma
⑤ Lymphatic malformation
Correct Answer: ③
Explanation: The combination of marked T2 hyperintensity, internal low-signal fibrous structures, strong enhancement, and vascularity is compatible with myxoid SFT. T2 hyperintensity alone would not be sufficient.
Question 2
Which combination is relevant to risk assessment in SFT?
① Blood pressure and heart rate
② Age, tumor size, mitotic activity, and necrosis
③ T1 and T2 signal alone
④ MRI examination time and contrast dose
⑤ Chest-pain severity
Correct Answer: ②
Explanation: Clinical and histopathologic variables such as age, tumor size, mitotic activity, and necrosis have been incorporated into SFT risk assessment models.
Question 3
A bright band on one side of a lesion and a dark band on the opposite side on sagittal T2-weighted imaging is attributed in this case to which phenomenon?
① Two different tumors
② Three-dimensional reconstruction
③ Chemical-shift artifact
④ Phase-encoding artifact
⑤ Intratumoral hemorrhage
Correct Answer: ③
Explanation: The described finding is interpreted as a type 1 chemical-shift artifact related to the frequency-encoding direction.
Conclusion
This case begins with a seemingly minor incidental finding: an approximately 2 cm superficial soft-tissue nodule discovered during CT angiography performed for chest pain.
Three years later, MRI changes the diagnostic conversation.
The lesion has enlarged to approximately 3–4 cm and demonstrates:
Slightly low T1 signal
Markedly high T2 signal
Thin internal low-signal structures
Strong enhancement
Prominent adjacent vessels
A superficial subcutaneous location without clear deep invasion in the described imaging
Taken together, these findings support consideration of myxoid solitary fibrous tumor.
The most important lesson is not that every growing superficial nodule represents SFT. Rather, it is that small size should never replace tissue characterization.
The radiologist should ask:
What is this lesion made of?
How does it enhance?
Does it contain fibrous and myxoid components?
Are there prominent vessels?
Has it changed over time?
Does an apparent imaging feature represent true pathology or artifact?
In this case, CT served as the detection tool, while MRI supplied the tissue-characterization information that made the lesion diagnostically meaningful.
Myxoid SFT is rare, and its limited literature means that imaging findings should not be used to make unsupported assumptions about biological behavior. Nevertheless, the combination of myxoid high T2 signal, internal low-signal fibrous structures, strong enhancement, and vascularity provides a useful radiologic pattern.
For modern medical imaging, the broader lesson is equally important: the value of an imaging examination often emerges from the integration of anatomy, tissue composition, enhancement, longitudinal comparison, and clinical context—not from any single image or isolated measurement.
Key Takeaways
Incidental superficial soft-tissue masses require characterization based on composition and behavior.
The initial CT in this case demonstrated a non-fatty soft-tissue nodule.
Three-year interval growth increased the importance of further characterization.
MRI demonstrated marked T2 hyperintensity and slightly low T1 signal.
Internal low-signal structures may correspond to fibrous or collagenous tissue.
Strong enhancement indicates vascularized solid tissue rather than a simple cyst.
Prominent peritumoral vessels are an important clue.
Myxoid SFT can combine myxoid, fibrous, and vascular imaging characteristics.
Chemical-shift artifact should not be mistaken for intrinsic tumor structure.
Imaging can suggest the diagnosis, but pathologic correlation remains important.
AI may assist detection, segmentation, and longitudinal comparison, but rare tumors remain challenging for automated classification.
Continue Learning
Readers interested in this case may continue with the following MediAI imaging topics:
CT and MRI Evaluation of Superficial Soft-Tissue Masses
T1 and T2 Signal Patterns in Soft-Tissue Tumors
MRI Differential Diagnosis of Myxoid Soft-Tissue Tumors
Solitary Fibrous Tumor: Imaging, Pathology, and Risk Assessment
The Role of Contrast Enhancement in Soft-Tissue Tumor Characterization
Chemical-Shift Artifact in MRI: Common Diagnostic Pitfalls
AI-Assisted Detection of Soft-Tissue Tumors
Longitudinal Imaging and Automated Tumor Growth Detection
References
F. D. Beaman, M. J. Kransdorf, T. R. Andrews, M. D. Murphey, L. K. Arcara, and J. H. Keeling, “Superficial soft-tissue masses: Analysis, diagnosis, and differential considerations,” RadioGraphics, vol. 27, no. 2, pp. 509–523, 2007. doi: 10.1148/rg.272065082.
D. T. Ginat, A. Bokhari, S. Bhatt, and V. Dogra, “Imaging features of solitary fibrous tumors,” American Journal of Roentgenology, vol. 196, no. 3, pp. 487–495, 2011. doi: 10.2214/AJR.10.4948.
O. J. Wignall, E. C. Moskovic, K. Thway, and J. M. Thomas, “Solitary fibrous tumors of the soft tissues: Review of the imaging and clinical features with histopathologic correlation,” American Journal of Roentgenology, vol. 195, no. 1, pp. W55–W62, 2010. doi: 10.2214/AJR.09.3379.
Z. G. Papathanassiou, M. Alberghini, P. Picci, et al., “Solitary fibrous tumors of the soft tissues: Imaging features with histopathologic correlations,” Clinical Sarcoma Research, vol. 3, no. 1, 2013. doi: 10.1186/2045-3329-3-1.
A. D. Baheti, S. H. Tirumani, M. H. Rosenthal, et al., “Myxoid soft-tissue neoplasms: Comprehensive update of the taxonomy and MRI features,” American Journal of Roentgenology, vol. 204, no. 2, pp. 374–385, 2015. doi: 10.2214/AJR.14.12888.
S. S. Shin, Y. Y. Jeong, and H. K. Kang, “Myxoid solitary fibrous tumor of the retroperitoneum: MRI findings with the pathologic correlation,” Korean Journal of Radiology, vol. 9, no. 3, pp. 279–282, 2008. doi: 10.3348/kjr.2008.9.3.279.
S. K. Lau, L. M. Weiss, and P. G. Chu, “Myxoid solitary fibrous tumor: A clinicopathologic study of three cases,” Virchows Archiv, vol. 454, no. 2, pp. 189–194, 2009. doi: 10.1007/s00428-008-0721-7.
K. Dantey and K. Cooper, “Myxoid solitary fibrous tumor: A study of three cases,” International Journal of Surgical Pathology, vol. 21, no. 4, pp. 358–362, 2013. doi: 10.1177/1066896912470166.
V. G. Swami, E. G. Demicco, A. Naraghi, and L. M. White, “Soft tissue solitary fibrous tumors of the musculoskeletal system: Spectrum of MRI appearances and characteristic imaging features,” Skeletal Radiology, vol. 51, no. 4, pp. 807–817, 2022. doi: 10.1007/s00256-021-03894-6.
E. G. Demicco, M. J. Wagner, R. G. Maki, et al., “Risk assessment in solitary fibrous tumors: Validation and refinement of a risk stratification model,” Modern Pathology, vol. 30, pp. 1433–1442, 2017. doi: 10.1038/modpathol.2017.54.
J. Tolstrup, A. Loya, N. Aggerholm-Pedersen, L. Preisler, and L. Penninga, “Risk factors for recurrent disease after resection of solitary fibrous tumor: A systematic review,” Frontiers in Surgery, vol. 11, 2024. doi: 10.3389/fsurg.2024.1332421.
Medical Disclaimer: This article is intended for medical education and does not replace professional diagnosis or treatment. Individual imaging findings and clinical decisions should be interpreted in the appropriate clinical context by qualified healthcare professionals.
Comments
Post a Comment